BG
PACB icon

Bellevue Group’s Pacific Biosciences PACB Stock Holding History

Bellevue Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-4,592,251
Closed -$17.2M – 172
2024
Q1 		$17.2M Sell
4,592,251
-2,724,877
-37% -$16M 0.26% 81
2023
Q4 		$71.8M Buy
7,317,128
+71,940
+1% +$588K 1.1% 27
2023
Q3 		$60.5M Sell
7,245,188
-297,641
-4% -$3.4M 0.97% 27
2023
Q2 		$100M Buy
7,542,829
+516,723
+7% +$6.28M 1.43% 21
2023
Q1 		$81.4M Buy
7,026,106
+547,181
+8% +$5.44M 1.18% 28
2022
Q4 		$53M Buy
6,478,925
+1,039,374
+19% +$8.96M 0.7% 45
2022
Q3 		$31.6M Sell
5,439,551
-521,678
-9% -$2.99M 0.45% 62
2022
Q2 		$26.3M Buy
5,961,229
+1,079,477
+22% +$6.56M 0.37% 73
2022
Q1 		$44.4M Buy
4,881,752
+3,328,729
+214% +$38.3M 0.52% 61
2021
Q4 		$31.8M Sell
1,553,023
-90,136
-5% -$2.18M 0.33% 84
2021
Q3 		$42M Hold
1,643,159
– – 0.43% 74
2021
Q2 		$57.5M Buy
1,643,159
+25,654
+2% +$746K 0.56% 61
2021
Q1 		$53.9M Sell
1,617,505
-80,674
-5% -$2.82M 0.57% 57
2020
Q4 		$44.1M Sell
1,698,179
-2,206,288
-57% -$37.5M 0.5% 58
2020
Q3 		$38.5M Sell
3,904,467
-4,459,274
-53% -$25.7M 0.53% 55
2020
Q2 		$28.9M Buy
8,363,741
+984,950
+13% +$3.35M 0.41% 61
2020
Q1 		$22.6M Buy
7,378,791
+1,644,482
+29% +$6.73M 0.44% 60
2019
Q4 		$29.5M Buy
5,734,309
+3,360,522
+142% +$17.1M 0.47% 52
2019
Q3 		$12.2M Buy
+2,373,787
New +$13.3M 0.23% 78
2018
Q4 		– Sell
-2,575,000
Closed -$13.9M – 141
2018
Q3 		$13.9M Buy
+2,575,000
New +$11M 0.88% 40

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group's PACB Position: Q2 2024 in Review

Bellevue Group sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 4,592,251 shares — an estimated $17.2M sold.

Bellevue Group first reported a position in PACB in Q3 2018 and held it in 20 quarters. The position peaked at $100M in Q2 2023. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

  • Bellevue Group reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
  • Bellevue Group sold 4,592,251 Pacific Biosciences shares in Q2 2024, an estimated $17.2M.
  • Bellevue Group first reported a position in Pacific Biosciences in Q3 2018 and held it in 20 quarters.
  • Bellevue Group's Pacific Biosciences position peaked at $100M in Q2 2023.
  • 228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on Bellevue Group's 13F filing for Q2 2024, filed 14 Aug 2024.